Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
Financing proceeds are expected to support clinical development milestones, while the merger and Nasdaq listing readiness remain conditional.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sernova Biotherapeutics (SEOVF) and Seraxis closed a US$11.2 million financing into Seraxis tied to their proposed merger to form BetaNova Biotherapeutics. The financing comprises convertible notes and common stock purchase warrants; the notes are expected to convert automatically into BetaNova common stock upon merger completion.
The companies expect proceeds to support SR-02 manufacturing, type 1 diabetes patient enrollment in Q4, and first Phase 1/2 dosing in Q1 2027 under an FDA-cleared investigational new drug application. Initial data are anticipated in H1 2027. Plans also target Nasdaq listing readiness in Q1 2027 and advancement of gene-edited SR-03 toward a regulatory submission in H2 2027. The merger remains subject to required approvals and closing conditions. Each company's shareholders are expected to collectively own approximately 50% of BetaNova on a non-diluted basis upon completion.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointUS$11.2 million financing into Seraxis closed, exceeding the previously announced US$10 million target. 38% of market cap
- Major pointDefinitive merger agreement signed September 7, 2026, combines Seraxis' cell programs and manufacturing with Sernova's Cell Pouch.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 1/2 enrollment of patients with type 1 diabetes is expected in Q4.
- Moderate point. Forward-looking: it has not happened yet and may not happen.SR-02 first dosing is expected in Q1 2027 under an FDA-cleared investigational new drug application.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Initial SR-02 clinical data are anticipated in H1 2027.
3 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.SR-02 manufacturing is expected to receive financing support for stem cell-derived pancreatic islet cells.
- Minor point. Forward-looking: it has not happened yet and may not happen.Nasdaq listing readiness is targeted for Q1 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.SR-03 advancement targets an investigational new drug application submission in the second half of 2027.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Convertible notes and common stock purchase warrants introduce potential dilution; notes are expected to convert upon merger completion.
- Minor pointProposed merger remains subject to required approvals and closing conditions.
- Minor point. Forward-looking: it has not happened yet and may not happen.Nasdaq listing readiness depends on satisfaction of applicable listing requirements and approvals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced the closing of the previously announced targeted US
The US
Proceeds from the financing are expected to support:
- cGMP manufacturing of SR-02, allogeneic stem cell-derived pancreatic islet cells;
- Enrollment of patients with T1D in Q4 for Phase 1 / 2 clinical trial;
- First patient dosing of SR-02 in Phase 1/2 clinical trial in Q1 2027 under an FDA-cleared IND with initial clinical data anticipated in H1 2027;
- Nasdaq listing readiness targeted for Q1 2027, subject to satisfaction of applicable listing requirements and approvals; and
- Advancement of SR-03, the next-generation gene-edited pancreatic islet cell program targeting immune evasion, toward an IND submission in the second half of 2027.
“This financing puts capital directly behind the milestones we have outlined for BetaNova as we passionately advance towards a potential functional cure for people living with T1D,” said Jonathan Rigby, President and Chief Executive Officer of Sernova. “With the financing now closed, we believe BetaNova is positioned to successfully compete with other companies in the T1D cell therapy space by entering the clinic in the near term. Our focus is on execution, while deploying capital efficiently.”
“Closing the financing provides the resources to advance the manufacturing activities required to support SR-02 islet cells and prepare for initiation of the Phase 1/2 clinical trial,” said Will Rust, Ph.D., President and Chief Executive Officer of Seraxis. “As we work toward completion of the Merger, our teams are aligned around a shared mission, a clear development strategy and a defined set of milestones for 2026 and 2027.”
Proposed Merger
Sernova and Seraxis entered into a definitive merger agreement on September 7, 2026, to form BetaNova, combining Seraxis’ stem cell-derived pancreatic islet programs and cGMP manufacturing capabilities with Sernova’s Cell Pouch Bio-hybrid Organ. The completion of the Merger is subject to required approvals and customary closing conditions. Upon completion, each of Sernova and Seraxis shareholders are expected to collectively own approximately
Noble Capital Markets, Inc. is acting as exclusive financial advisor to Sernova in connection with the proposed Merger.
About the Financing
The US
ABOUT BETANOVA BIOTHERAPEUTICS, INC.
BetaNova Biotherapeutics, Inc. is the proposed combined company of Sernova Biotherapeutics Inc. and Seraxis Holdings, Inc. Subject to completion of the proposed transaction, BetaNova will be a clinical-stage regenerative medicine company focused on advancing cell-replacement therapies for type 1 diabetes. BetaNova will combine Seraxis' stem cell-derived islet cell and cGMP manufacturing platform with Sernova's Cell Pouch Bio-hybrid Organ.
ABOUT SERNOVA BIOTHERAPEUTICS INC.
Sernova Biotherapeutics Inc. is a clinical-stage company developing a regenerative medicine solution for T1D that combines its Cell Pouch implantation device, deep clinical experience in the engraftment of functional pancreatic cells, and therapeutic cells to create a Bio-hybrid, functional surrogate endocrine organ.
ABOUT SERAXIS HOLDINGS, INC.
Seraxis Holdings, Inc. develops stem cell-derived pancreatic islets under cGMP manufacturing processes. Seraxis’ mission is to demonstrate safety and potency of its islets in T1D patients without immune suppression therapy. To accomplish this goal, its lead allogeneic product, SR-02, is paired with an immune tolerizing strategy. Seraxis’ follow-on product SR-03 adds gene edits to SR-02 that increase compatibility with the host and potentially enhance long-term engraftment without immune suppression.
For Further Information Contact:
Investor Relations
David Burke
Vice President, Investor Relations
Sernova Biotherapeutics Inc.
(917) 751-5713
David.Burke@sernova.com
Media
Gloria Gasaatura
VP, LifeSci Communications
SernovaPR@lifescicomms.com
Forward-Looking Information
This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws. Particularly statements and information regarding the proposed Merger of Sernova and Seraxis, the anticipated formation of BetaNova, the anticipated use of proceeds from the financing, manufacturing of SR-02, the timing of patient dosing and availability of clinical data, development of SR-03, and the anticipated completion of the Merger. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information.
Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. These statements include, without limitation, statements regarding the receipt, in a timely manner, of shareholder, court and regulatory approvals in respect of the Merger, the expected closing date for the Merger and BetaNova’s leadership, business prospects and operations following closing of the Merger and the anticipated use of proceeds and results thereof from the non-brokered financing. Undue reliance should not be placed on forward-looking information. The forward-looking information in this press release is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Further, forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks relating to regulatory interactions, manufacturing, patient recruitment, clinical development, financing requirements, completion of the proposed Merger and satisfaction of applicable Nasdaq listing requirements.
Additional information about the risks and uncertainties of Sernova’s business and material risk factors or assumptions on which information contained in forward-looking information is based is provided in Sernova’s disclosure materials, including Sernova’s most recently filed news release, annual information form and any subsequently-filed interim management’s discussion and analysis, which are available under our profile on SEDAR+ at www.sedarplus.ca. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents our expectations as of the date of this news release and is subject to change after such date. Sernova disclaims any intention or obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much financing did Sernova and Seraxis close for the proposed BetaNova merger?
The companies closed US$11.2 million in financing into Seraxis through convertible notes and common stock purchase warrants. The financing was non-brokered. Upon merger completion, the notes are expected to convert automatically into BetaNova common stock.
When is BetaNova's SR-02 Phase 1/2 trial expected to begin dosing patients?
First patient dosing of SR-02 is expected in Q1 2027 under an FDA-cleared investigational new drug application. Patient enrollment is expected in Q4, and initial clinical data are anticipated in H1 2027.
Who participated in the Sernova and Seraxis merger financing?
Participants included insiders, existing shareholders and new investors. Named participants included Dr. Steven Sangha / Arlo Investments; Sernova management Jonathan Rigby, James Parsons, Marylyn Rigby and David Burke; and Seraxis management Will Rust and Carole Welsch.